



### **SPEAKERS**

# DR CHRISTOPHER BURGESS

Burgess Analytical Consultancy, UK

### DR THOMAS FÜRST

Boehringer Ingelheim

### **DR KERSTIN PAULI**

Bayer HealthCare Pharmaceuticals

### **DR JOCHEN SCHER**

Boehringer Ingelheim

# Dissolution Testing

Visit the Dissolution Laboratories at Bayer HealthCare Pharmaceuticals in Berlin

2 - 4 November 2011, Berlin, Germany

### **HIGHLIGHTS:**

- Regulatory Requirements (Pharmacopoeias, etc.)
- Equipment Qualification (USP Requirements versus FDA Guidance)
- Development of Dissolution Methods
  - How to set Specifications
  - Analytical Validation
  - Practical Recommendations
- OOS Results in Dissolution Testing
- The Role of Biowaivers During Drug Product Development
- Dissolution Profile Comparison
- Automation of Dissolution Methods



### **Dissolution Testing**

2-4 November 2011, Berlin, Germany

### **Objectives**

This GMP Education Course on Dissolution Testing aims at providing delegates with a sound understanding of the principles and practices in dissolution testing, which has become increasingly important in pharmaceutical industry.

A visit of the new dissolution laboratory at Bayer HealthCare Pharmaceuticals is part of the course programme.

### **Background**

The dissolution test is a key performance test of solid oral dosage forms in drug development and quality control. In these fields it is used to assure batch-to-batch quality, to provide process control and to substitute in vivo studies under certain circumstances – mainly for solid oral dosage forms.

Several authorities (e.g. FDA, EMA) issued guidances on this topic dealing with

- approaches for setting specifications
- the relation to the biopharmaceutical characteristics of the drug substance
- dissolution methodology, apparatus, and operating conditions,
- validation of the dissolution methodology
- statistical methods for comparing dissolution profiles
- approaches for substitution of BE studies (biowaiver) and
- approaches to establish in vitro in vivo correlations (IVIVC).

These items will be covered in this course. In addition, the questions and expectations of the European Medicines Agency (EMA) and of the pharmacopoeias (Ph.Eur. 2.9.3 and USP General Chapter <711> and General Information <1092> including USP Reference Standard Tablets for the Performance Verification Test will be discussed.

The objective of this course is to cover all aspects of dissolution testing with a focus on practical examples. Workshops are an essential part of the course in order to encourage the exchange of experience and to allow interactive and in depth discussions of the subject.

### **Target Audience**

This conference is dedicated to scientists and managers in the pharmaceutical industry working in:

- Quality control
- Quality assurance
- Analytical development
- Pharmaceutical Development
- Research and development
- Regulatory Affairs

The course is also intended for participants from contract laboratories, regulatory authorities, and inspectorates.

### Moderator

DR CHRISTOPHER BURGESS, Burgess Analytical Consultancy Ltd., UK

### **Programme**

### Dissolution Testing and Qualification from a Pharmacopoeial Perspective

- Requirements of the USP & EP
- Qualification and calibration
- Harmonisation of methods
- Key differences between the USP and EP
- FDA and ASTM activities
- Related methodologies: disintegration and friability DR CHRISTOPHER BURGESS, Burgess Analytical Consultancy

### **Regulatory Requirements and Beyond**

- What guidelines tell us about
  - Biorelevant methods
  - In vivo in vitro correlations
  - Profile Comparison
  - Setting of Specifications

and how this is put into practice

DR THOMAS FÜRST, Boehringer Ingelheim

### Programme (cont'd)

### **Automation in Dissolution Testing**

- Objectives of automation
- Presentation of different types of dissolution systems:
  - area of application
  - discussion about pros and cons
- Innovation in automation: the new RoboDis®

DR KERSTIN PAULI, Bayer Health Care Pharmaceuticals

### **WORKSHOP I**

### **Equipment Qualification including USP Performance Verification**

- Control of mechanical, technical and dimensional tolerances
- Computerised system validation aspects
- Holistic testing of dissolution systems

Moderator: Dr Christopher Burgess

### **Setting Specifications for Dissolution Methods**

- Setting specifications for various formulations:
  - Immediate Release Formulations
  - Modified Release Formulations
  - Delayed Release Formulations
  - Special Dosage Forms (e.g. replacement of dissolution by disintegration)
- Special needs in pharmaceutical industry
- Requirements of Pharmacopoeias
- Presentation of relevant Guidelines

DR KERSTIN PAULI, Bayer HealthCare Pharmaceuticals

### **WORKSHOP II**

### **Setting Specifications**

The aim of the workshop is to demonstrate on certain case studies:

- how to adopt the requirements of the various Guidelines and Pharmacopoeias
- how to assign acceptance criteria for different types of formulations

Moderator: Dr Kerstin Pauli

### **Development of Dissolution Methods with regard to Quality Control**

- Points to Consider During Method Development
  - Dissolution Apparatus
  - Medium Selection and
  - Key Operating Parameters
- Discriminatory Capability of the Dissolution Method
- Dissolution methods for developing an IVIVC

DR JOCHEN SCHER, Boehringer Ingelheim

### **Analytical Validation of Dissolution Testing Methods**

- Pharmacopoeial and Regulatory Recommendations (e.g. ICH Q2 (R1) and USP <1092>)
- Validation characteristics:
  - Specificity, Linearity, Precision, Accuracy and Robustness,
  - Furthermore:
    - filter-validation
    - selecting the right deaeration method
    - validation of automated methods
- Some practical recommendations for performing the validation and recommended acceptance criteria
- Dissolution method transfer

**DR JOCHEN SCHER**, Boehringer Ingelheim

### **WORKSHOP III**

### **Analytical Validation of Dissolution Methods**

Putting theory to work (case studies):

- Develop validation protocol for validation of dissolution methods for different solid oral dosage forms
- Pitfalls in performing the experiments

Moderator: Dr Jochen Scher

### Programme (cont'd)

### **OOS Results in Dissolution Testing**

- When is a result OOS and when is it not?
- Performance verification issues
- Failure investigations in dissolution testing
- Are statistical outlier tests useful as part of dissolution test failure investigations?
- Documenting the outcome of the failure investigation

DR CHRISTOPHER BURGESS, Burgess Analytical Consultancy

### The Importance of Biowaiving in Drug Product Development

- Overview of regulations
- Differences between US/EU and Japan
- The role of biowaivers during drug product development
- Types of biowaivers e.g. BCS based, proportional similar products
- What data are necessary
  - how to select batches
  - how many batches need to be compared
  - media selection
- Case Studies (Phase III commercial, additional strength, fixed dose combination)

DR THOMAS FÜRST, Boehringer Ingelheim

### **Dissolution Profile Comparison; Approaches and Issues**

- Dissolution processes and data variability
- What are we trying to compare?
- What do the agencies specify?
- Model independent approaches
- Examples of approaches

DR CHRISTOPHER BURGESS, Burgess Analytical Consultancy

## Application for a Marketing Authorisation: Data Required for the Justification and for the Submission of Dissolution Methods

- Rationale for determining method parameters
- Justification of discriminatory power
- Proof of robustness of the dissolution method
- Selection of the analytical method
- Method transfer on automatic systems

DR KERSTIN PAULI, Bayer Health Care Pharmaceuticals

### Visit of the Dissolution Laboratories at Bayer HealthCare Pharmaceuticals, Berlin

In the afternoon of the first course day all participants and speakers are invited to a guided tour to the new dissolution laboratory at Bayer HealthCare Pharmaceuticals in Berlin. The dissolution lab is equipped with various automated dissolution systems applicable to cover multiple aspects occurring during research and development:



- The new RoboDis: several fully automated robotic system (equipped with HPLC-, UV/ VIS- and fibre optics technology) developed in cooperation with ERWEKA
- Several semi-automated UV/VIS systems
- Semi-automated "Paddle-over disk" dissolution system



 Fully automated Sotax AT 70 smart dissolution systems



■ Various semi-automated HPLC-systems

There will be a bus transfer to the laboratory and back to the hotel.

The number of participants for the lab visit is limited.

### **Speakers**

### **DR CHRISTOPHER BURGESS**



Burgess Analytical Consultancy Limited, UK

Dr Burgess is a Chartered Chemist and has more than 36 years experience in the pharmaceutical industry primarily with Glaxo in Quality Assurance and Analytical R&D. He is a "Qualified Person" and a member of the European QP Association advisory board. He has been appointed to the United States Pharmacopoeia's Council of Experts 2010 to 2015 and is a visiting professor of the University of

Strathclyde's School of Pharmacy and Biomedical Sciences (SIPBS). In addition, he is the chairman of the ECA Analytical Quality Control Group and a member of the Executive committee of European Compliance Academy.

### DR THOMAS FÜRST



Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
Dr Fürst is Senior Principal Scientist at the Development Unit of Boehringer Ingelheim. He is responsible for the scientific quality of submissions and the QOS.
Before joining Boehringer Ingelheim, Dr Fürst was with Schering AG, Berlin, where he worked in a production facility for oral dosage forms and the analytical

development department before heading the Pharmaceutical Development Services group of Schering AG, Berlin.

### **DR KERSTIN PAULI**



Bayer HealthCare Pharmaceuticals, Berlin, Germany

Kerstin Pauli studied Food Chemistry and Pharmacy at the University of Bonn and received her PhD in Pharmaceutical Analytics. In her position as head of a group of project laboratories in Global Drug Development within Bayer Health-Care Pharmaceuticals she is responsible for all aspects regarding the analytical part of product development. In her first position she was specialised in the area

of dissolution testing (including development and validation of dissolution methods, submission of development projects and handling of post approval changes, life cycle management and patent protection of market products) and also for automation in dissolution testing (Robot Technology).

### **DR JOCHEN SCHER**



Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
Dr. J. Scher studied pharmacy and conducted his PhD at the University of Saarland at the Institute of Pharmacognosy and Analytical Phytochemistry and part time at the University of Otago. He is a specialised pharmacist for pharmaceutical analytics and for six years he is working at Boehringer Ingelheim GmbH & Co.

KG in Biberach (Germany). He is laboratory head in the Analytical Development and responsible for a dissolution unit.

### **Social Event**

We are looking forward to welcome all participants and speakers to a nice evening in a relaxed atmosphere after the first course day.

# **GMP Certification Programme**


This course is recognised within the GMP Certification Programme Module "Pharmaceutical Quality Control Manager". By attending selected seminars, the participant can acquire an additional certificate. We offer the following certification modules:


- ECA Validation Manager
- ECA QA Manager
- ECA API Production Manager
- ECA Quality Control Manager
- ECA Technical Operations Manager
- ECA Computer Validation Manager
- ECA Regulatory Affairs Manager
- ECA Microbiological Laboratory Manager
- ECA Sterile Production Manager
- ECA Biotech Manager
- ECA Pharmaceutical Development Manager


On the internet at www.gmp-compliance.org you will find a text explaining which seminars are recognised for which certificates. Or you send an e-mail to info@gmp-compliance.org or a fax to +49-6221-84 44 64 with the request for information about the GMP Certification Programme. We will then send you our brochure on the topic.

### **Easy Registration**









#### **Date**

Wednesday, 2 November 2011, 9.00 h - 18.00 h (Registration and coffee 8.30 h - 9.00 h) Thursday, 3 November 2011, 8.30 h - 18.30 h Friday, 4 November 2011, 08.30 - 15.30 h

Esplanade Grand Hotel Berlin Lützowufer 15 10785 Berlin Germany Phone: +49 / (0) 30 / 25478 0 Fax: +49 / (0) 30 / 25478 8617

ECA Members € 1,790.- per delegate plus VAT APIC Members € 1,890.- per delegate plus VAT (does not include ECA Membership) Non-ECA Members € 1,990.- per delegate plus VAT EU GMP Inspectorates € 995.- per delegate plus VAT The conference fee is payable in advance after receipt of invoice and includes conference documentation, dinner on the first day, lunch on three days and all refreshments. VAT is reclaimable.

### Accommodation

CONCEPT HEIDELBERG has reserved a limited number of rooms in the conference hotel. You will receive a room reservation form when you have registered for the event. Please use this form for

your room reservation or be sure to mention "VA 6920 ECA Event" to receive the specially negotiated rate for the duration of your stay. Reservation should be made directly with the hotel not later than 30 September 2011. Early reservation is recommended.

### Registration

Via the attached reservation form, by e-mail or by fax message. Or you register online at www.gmp-compliance.org.

### Conference language

The official conference language will be English.

### **Organisation and Contact**

**CONCEPT HEIDELBERG** P.O. Box 10 17 64 69007 Heidelberg, Germany Phone +49 (0) 62 21/84 44-0, Fax +49 (0) 62 21/84 44 34 E-mail: info@concept-heidelberg.de www.concept-heidelberg.de

### For questions regarding content:

Dr Günter Brendelberger (Operations Director) at +49-62 21 / 84 44 39, or per e-mail at brendelberger@concept-heidelberg.de.

For questions regarding reservation, hotel, organisation etc.:

Susanne Ludwig (Organisation Manager) at +49-62 21 / 84 44 44, or per e-mail at ludwig@concept-heidelberg.de.

If the bill-to-address deviates from the specification to the right, please fill out here:	Reservation Form (Please complete in full)	<b>♣</b> +49 6221 84 44 34
	<b>Dissolution Testing</b> 2 - 4 November 2011, Berlin, Germany	
	□ Mr □ Ms	
	Title, first name, surname	
	Company	
	Department	
	Important: Please indicate your company's VAT ID Number	
CONCEPT HEIDELBERG P.O. Box 10 17 64 Fax +49 (0) 6221/84 44 34	Please indicate the Purchase Order Number, if applicable	
	Street / P.O. Box	
69007 Heidelberg Germany	City Zip Code	
	Country	
	Phone / Fax	_
	E-Mail (Please fill in)	

If you cannot attend the conference you have two options:

- 1. We are happy to welcome a substitute colleague at any time.

  2. If you have to cancel entirely we must charge the following processing fees: Cancellation
- until 2 weeks prior to the conference 10 %
- until 1 weeks prior to the conference 50 %
   within 1 week prior to the conference 100 %
- CONCEPT HEIDELBERG reserves the right to change the materials, instructors, or speakers without notice or to cancel an event. If the event must be cancelled, registrants will be notified as soon as possible

and will receive a full refund of fees paid. CONCEPT HEIDELBERGwill not be responsible for discount airfare penalties or other costs incurred due to a cancellation.

Terms of payment: Payable without deductions within 10 days after receipt of invoice.

Important: This is a binding registration and above fees are due in case of cancellation or non appearance. If you cannot take part, you have to inform us in writing. The cancellation fee will then be calculated according to the point of time at which we receive your message. In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receipt of payment will not be confirmed)!